TY - JOUR
T1 - Responsiveness of the national eye institute visual function questionnaire-25 to visual acuity gains in patients with diabetic macular edema
T2 - Evidence from the RIDE and RISE Trials
AU - Suñer, Ivan J.
AU - Bressler, Neil M.
AU - Varma, Rohit
AU - Dolan, Chantal M.
AU - Ward, James
AU - Turpcu, Adam
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Purpose: To evaluate the responsiveness of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in patients with diabetic macular edema using data from the RIDE and RISE trials. Methods: Patients were randomized to monthly intravitreal ranibizumab 0.3 mg, 0.5 mg, or sham injections for 2 years. The NEI VFQ-25 was administered at baseline and at Months 6, 12, 18, and 24. The least-squares mean change in NEI VFQ-25 for ≥15 letters gained or lost was derived from analysis of covariance models. Results: The mean improvement in NEI VFQ-25 composite score associated with a ≥15-letter gain in best-corrected visual acuity over 24 months was 9.0 (95% confidence interval, 6.3-11.7) points in RIDE and 7.1 (95% confidence interval, 4.7-9.6) points in RISE. In patients who lost ≥15 letters, the mean worsening in overall NEI VFQ-25 composite score was -6.6 (95% confidence interval, -13.6 to 0.5) in RIDE and -2.7 (95% confidence interval, -8.9 to 3.5) in RISE. Conclusion: This exploratory analysis of data from the RIDE and RISE studies supports the responsiveness of the NEI VFQ-25 to changes in best-corrected visual acuity over time in patients with diabetic macular edema.
AB - Purpose: To evaluate the responsiveness of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in patients with diabetic macular edema using data from the RIDE and RISE trials. Methods: Patients were randomized to monthly intravitreal ranibizumab 0.3 mg, 0.5 mg, or sham injections for 2 years. The NEI VFQ-25 was administered at baseline and at Months 6, 12, 18, and 24. The least-squares mean change in NEI VFQ-25 for ≥15 letters gained or lost was derived from analysis of covariance models. Results: The mean improvement in NEI VFQ-25 composite score associated with a ≥15-letter gain in best-corrected visual acuity over 24 months was 9.0 (95% confidence interval, 6.3-11.7) points in RIDE and 7.1 (95% confidence interval, 4.7-9.6) points in RISE. In patients who lost ≥15 letters, the mean worsening in overall NEI VFQ-25 composite score was -6.6 (95% confidence interval, -13.6 to 0.5) in RIDE and -2.7 (95% confidence interval, -8.9 to 3.5) in RISE. Conclusion: This exploratory analysis of data from the RIDE and RISE studies supports the responsiveness of the NEI VFQ-25 to changes in best-corrected visual acuity over time in patients with diabetic macular edema.
KW - National Eye Institute Visual Function Questionnaire-25
KW - diabetic macular edema
KW - visual acuity
UR - http://www.scopus.com/inward/record.url?scp=84988735033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988735033&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000001316
DO - 10.1097/IAE.0000000000001316
M3 - Article
C2 - 27668928
AN - SCOPUS:84988735033
SN - 0275-004X
VL - 37
SP - 1126
EP - 1133
JO - Retina
JF - Retina
IS - 6
ER -